List of Topics | GCNN 2027

01 Topics

Every session topic at GCNN 2027.

A complete, searchable index of session topics across 35 scientific sessions. Use this page to plan your attendance or to find the right call for your abstract submission.

01 Track

Stroke & Cerebrovascular Disease

Thrombectomy, mobile stroke units and stroke prevention.

Track details

Tenecteplase vs alteplase: AcT, ATTEST-2, and dosing strategies
Late-window and large-core thrombectomy: SELECT2, ANGEL-ASPECT
Medium and distal vessel occlusion thrombectomy trials
Mobile stroke units and direct-to-angio-suite workflows
Factor XI inhibitors (asundexian, abelacimab) in secondary prevention
Cerebral small vessel disease and vascular cognitive impairment
Intracerebral hemorrhage: bundle care, minimally invasive evacuation

02 Track

Alzheimer’s & Dementia

Anti-amyloid therapies, biomarkers and early detection.

Track details

Lecanemab and donanemab: long-term efficacy, ARIA monitoring, APOE4 stratification
Plasma p-tau217 and the blood biomarker triage pathway
Tau-directed therapeutics: antisense oligonucleotides and active immunotherapy
GLP-1 receptor agonists in neurodegeneration: evoke, evoke+ readouts
Lewy body and frontotemporal dementia: TDP-43 and progranulin programs
Subcutaneous lecanemab and at-home administration models
Preclinical AD: DIAN-TU, AHEAD 3-45 and primary prevention

03 Track

Multiple Sclerosis

BTK inhibitors, remyelination and progressive MS.

Track details

BTK inhibitors in MS: tolebrutinib HERCULES, evobrutinib, fenebrutinib
Anti-CD20 therapies: ocrelizumab, ofatumumab, ublituximab subcutaneous
Progression independent of relapse activity (PIRA) and smoldering MS
Remyelination strategies: clemastine, elezanumab, anti-LINGO-1
EBV as a causal driver and EBV-directed T-cell therapies
Serum neurofilament light and GFAP as monitoring biomarkers
High-efficacy first vs escalation: DELIVER-MS, TREAT-MS

04 Track

Parkinson’s & Movement Disorders

Advanced therapies, DBS, GBA-targeted treatments.

Track details

GBA1 and LRRK2 stratified trials: ambroxol, BIIB122, BIA 28-6156
Subcutaneous levodopa pumps: ND0612, foslevodopa-foscarbidopa
Adaptive closed-loop DBS and directional leads
MRI-guided focused ultrasound: subthalamotomy, pallidotomy, tremor
Alpha-synuclein seed amplification assays as a biological diagnostic
Disease modification: prasinezumab, GLP-1 agonists (exenatide, lixisenatide)
Atypical parkinsonism: PSP, MSA tau and synuclein programs

05 Track

Epilepsy

Drug-resistant epilepsy, surgical approaches and genetic epilepsies.

Track details

Cenobamate and the new wave of focal-epilepsy ASMs
Genetic epilepsies: STK-001 for Dravet, ganaxolone for CDKL5
SCN2A, SCN8A, KCNQ2 precision medicine and ASOs
MRI-guided laser interstitial thermal therapy and robotic SEEG
Responsive neurostimulation (RNS) and ANT-DBS long-term outcomes
Focused ultrasound for hypothalamic hamartoma and tremor-epilepsy
SUDEP risk stratification and wearable seizure detection

06 Track

Neuromuscular Disease

ALS, SMA gene therapy and neuropathies.

Track details

SMA: nusinersen, onasemnogene abeparvovec, risdiplam comparative outcomes
Duchenne: Elevidys gene therapy, exon-skipping ASOs, givinostat
ALS: tofersen for SOD1, AMX0035 PHOENIX, C9orf72 and FUS ASOs
Neurofilament light as a trial endpoint and accelerated-approval pathway
Myasthenia gravis: FcRn antagonists (efgartigimod, rozanolixizumab) and C5 inhibitors
CIDP and autoimmune neuropathies: nodal/paranodal antibodies
Charcot-Marie-Tooth and inherited neuropathy gene-therapy pipeline

07 Track

Headache Medicine

CGRP antagonists, cluster headache and chronic migraine.

Track details

CGRP monoclonal antibodies: long-term safety, switching, pregnancy data
Gepants: atogepant, rimegepant, ubrogepant, zavegepant nasal
Lasmiditan and non-triptan acute therapy in cardiovascular risk
Cluster headache: galcanezumab, occipital nerve and SPG stimulation
Neuromodulation: REN, nVNS, eTNS in acute and preventive care
Pediatric and adolescent migraine treatment paradigms
Medication overuse headache: detoxification and bridging strategies

08 Track

Neuro-Oncology

Glioblastoma, brain metastases and novel immunotherapies.

Track details

Vorasidenib in IDH-mutant glioma: INDIGO, sequencing with chemoradiation
Glioblastoma CAR-T: GD2, EGFRvIII, IL-13Ra2 and intrathecal delivery
Tumor treating fields and integration with chemoradiation
Pediatric low-grade glioma: BRAF/MEK inhibitors, type II RAF
Brain metastases: HER2-ADCs (T-DXd), tucatinib, and SRS
Leptomeningeal disease: intrathecal therapy and proton CSI
Liquid biopsy and CSF circulating tumor DNA for monitoring

09 Track

Clinical Neuroscience & AI

Digital biomarkers, seizure detection and imaging AI.

Track details

Brain-computer interfaces: Neuralink, Synchron, BrainGate clinical readouts
Speech and motor decoding cortical implants for paralysis and ALS
AI stroke triage: Viz.ai, RapidAI and door-to-puncture impact
Foundation models for neuroimaging: MS, AD, glioma segmentation
Wearable seizure forecasting and ambulatory EEG analytics
Digital biomarkers: smartphone gait, speech, cognition in PD and AD
Ambient AI scribes and equitable deployment in neurology clinics

Have research aligned to one of these topics?

Submit your abstract by January 20, 2027. Oral and poster presentations are welcome across all nine tracks.

Submit Abstract